Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Assessment Only Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

NCT05384262
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Placebo, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

NCT06828666
View directory record Official record
Conditions
Osteoarthritis of Knee
Interventions
Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo)
Biological · Other
Lead sponsor
Britecyte
Network
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Baltimore, Maryland • Hagerstown, Maryland • Oxon Hill, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Study on Diurnal Variation

NCT01806051
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
Kuvan
Drug
Lead sponsor
Dr. Linda Randolph
Other
Eligibility
4 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

NCT06585462
View directory record Official record
Conditions
Cardiometabolic Disease
Interventions
AMG 513, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
13
States / cities
Anaheim, California • Lake Forest, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Total Knee Arthroplasty Biomechanics

NCT03671954
View directory record Official record
Conditions
Total Knee Arthroplasty (TKA)
Interventions
Home Strengthening Exercises, Standard Physical Therapy, Preoperative Assessments
Behavioral · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
4
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Evaluation of the Yes You Can... Make Smart Choices Curriculum

NCT05320666
View directory record Official record
Conditions
Pregnancy in Adolescence, Adolescent Health
Interventions
Yes You Can…Make Smart Choices! (YYC…MSC!) program
Behavioral
Lead sponsor
New Jersey Physicians Advisory Group
Other
Eligibility
10 Years to 21 Years
Enrollment
2,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
13
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

NCT05630846
View directory record Official record
Conditions
Measles; Mumps; Rubella; Chickenpox, Measles
Interventions
Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of NAV-240 in Healthy Volunteers

NCT06181786
View directory record Official record
Conditions
Healthy
Interventions
NAV-240, Placebo
Drug
Lead sponsor
Navigator Medicines, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

NCT00739973
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 29, 2026, 3:59 PM EDT
Active, not recruiting Phase 3 Interventional

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
View directory record Official record
Conditions
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions
TAS6417
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

NCT05388903
View directory record Official record
Conditions
Netherton Syndrome
Interventions
DS-2325a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 29, 2026, 3:59 PM EDT
Recruiting Not applicable Interventional

To Improve Depressive Symptoms Using a Web-App

NCT05405803
View directory record Official record
Conditions
Depression
Interventions
Web-App based Lifestyle Physical Activity Promotion Program, The Centers for Disease Control and Prevention (CDC) website on depression and physical activity guidelines
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

NCT03657342
View directory record Official record
Conditions
Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions
Liposomal Cyclosporine A, standard of care
Drug
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 29, 2026, 3:59 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

NCT00485134
View directory record Official record
Conditions
Shigellosis
Interventions
240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Not applicable Interventional

Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders

NCT01243606
View directory record Official record
Conditions
Anxiety Disorders, Mood Disorders
Interventions
Single Diagnosis Treatment Protocol, Unified Protocol (UP)
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Not applicable Interventional

The Use of Telerehabilitation to Improve Movement Outcomes for Patients With Parkinson Disease

NCT06246747
View directory record Official record
Conditions
Parkinson Disease
Interventions
In clinic physical therapy, Telerehabilitation only
Other
Lead sponsor
Wizecare
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 29, 2026, 3:59 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dyadic Financial Incentive Treatments for Dual Smoker Couples

NCT06296849
View directory record Official record
Conditions
Smoking, Cigarette
Interventions
Financial Incentive Treatment (FIT)
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Athens, Georgia • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

NCT06205615
View directory record Official record
Conditions
Wound Bleeding
Interventions
BXP154B, Placebo, Punch Biopsy
Drug · Procedure
Lead sponsor
Bio 54, LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects

NCT02145234
View directory record Official record
Conditions
Healthy Adults
Interventions
BMS-986089, Placebo matching with BMS-986089
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 29, 2026, 3:59 PM EDT
Recruiting Phase 2 Interventional

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

NCT07660835
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
6 Months to 23 Months
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
lufepirsen high dose, Vehicle, lufepirsen low dose
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
2 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

NCT05139121
View directory record Official record
Conditions
Contraception
Interventions
MR-100A-01
Drug
Lead sponsor
Mylan Technologies Inc.
Industry
Eligibility
16 Years and older · Female only
Enrollment
1,320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
96
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Endpoint Study of Ivermectin 0.5% Lotion

NCT03301649
View directory record Official record
Conditions
Head Lice
Interventions
Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
6 Months and older
Enrollment
905 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 29, 2026, 3:59 PM EDT